Dr. Peter McCullough's substack below reminds us about the 4 pillars of Pandemic Response & at the core is the seminal 'early treatment' paper we wrote; McCullough as 1st author, Zelenko as senior

by Paul Alexander

I was second author as I helped McCullough and Risch do the writing; note Dr. Ramin Oskoui is on this paper as is Ladapo etc. This paper set early treatment tone globally; now added nasal-oral rinse



Courageous Discourse™ with Dr. Peter McCullough & John Leake
Four Pillars of Pandemic Response
Watch now (7 min) | By Peter A. McCullough, MD, MPH Dr. Peter McCullough presented for hundreds of prominent doctors and civic leaders in Panama City on "The Four Pillars of Pandemic Response" and the principles of treatment of SARS-CoV-2 infection and COVID-19 infection. The “Four Pillars” were originally presented to the US Senate on November 19, 2020, and published late…
Read more

‘The SARS-CoV-2 virus spreading across the world has led to surges of COVID-19 illness, hospitalizations, and death. The complex and multifaceted pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the devastating illness. In countries where therapeutic nihilism is prevalent, patients endure escalating symptoms and without early treatment can succumb to delayed in-hospital care and death. Prompt early initiation of sequenced multidrug therapy (SMDT) is a widely and currently available solution to stem the tide of hospitalizations and death. A multipronged therapeutic approach includes 1) adjuvant nutraceuticals, 2) combination intracellular anti-infective therapy, 3) inhaled/oral corticosteroids, 4) antiplatelet agents/anticoagulants, 5) supportive care including supplemental oxygen, monitoring, and telemedicine. Randomized trials of individual, novel oral therapies have not delivered tools for physicians to combat the pandemic in practice. No single therapeutic option thus far has been entirely effective and therefore a combination is required at this time. An urgent immediate pivot from single drug to SMDT regimens should be employed as a critical strategy to deal with the large numbers of acute COVID-19 patients with the aim of reducing the intensity and duration of symptoms and avoiding hospitalization and death.’